BRPI0720251B8 - derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo - Google Patents

derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo

Info

Publication number
BRPI0720251B8
BRPI0720251B8 BRPI0720251A BRPI0720251A BRPI0720251B8 BR PI0720251 B8 BRPI0720251 B8 BR PI0720251B8 BR PI0720251 A BRPI0720251 A BR PI0720251A BR PI0720251 A BRPI0720251 A BR PI0720251A BR PI0720251 B8 BRPI0720251 B8 BR PI0720251B8
Authority
BR
Brazil
Prior art keywords
compounds
compound
combination
product
pharmaceutical composition
Prior art date
Application number
BRPI0720251A
Other languages
English (en)
Inventor
Koul Anil
Emile Georges Guillemont Jérôme
Jozef Lodewijk Marcel Andries Koenraad
Madeleine Simone Motte Magali
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0720251A2 publication Critical patent/BRPI0720251A2/pt
Publication of BRPI0720251B1 publication Critical patent/BRPI0720251B1/pt
Publication of BRPI0720251B8 publication Critical patent/BRPI0720251B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo. a presente invenção refere-se a novos derivados de quinolina substituída de acordo com a fórmula geral (la) ou formula geral (lb): incluindo qualquer forma estereoquimicamente isomérica desse composto, um sal farmaceuticamente aceitável desse composto, uma forma de n-óxido desse composto ou um solvato desse composto. os compostos reivindicados são úteis para o tratamento de uma infecção bacteriana. também reivindicada é uma composição que compreende um veículo farmaceuticamente aceitável e, como ingrediente ativo, uma quantidade terapeuticamente eficaz dos compostos reivindicados, o uso dos compostos reivindicados ou composições para a produção de um medicamento para o tratamento de uma infecção bacteriana e um processo para preparação dos compostos reivindicados.
BRPI0720251A 2006-12-06 2007-12-04 derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo BRPI0720251B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125521 2006-12-06
EP06125521.2 2006-12-06
PCT/EP2007/063315 WO2008068269A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (3)

Publication Number Publication Date
BRPI0720251A2 BRPI0720251A2 (pt) 2014-01-07
BRPI0720251B1 BRPI0720251B1 (pt) 2020-10-06
BRPI0720251B8 true BRPI0720251B8 (pt) 2021-05-25

Family

ID=37944337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720251A BRPI0720251B8 (pt) 2006-12-06 2007-12-04 derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo

Country Status (30)

Country Link
US (1) US7998979B2 (pt)
EP (1) EP2086941B1 (pt)
JP (1) JP5356245B2 (pt)
KR (1) KR101490221B1 (pt)
CN (1) CN101541752B (pt)
AR (1) AR064150A1 (pt)
AT (1) ATE465994T1 (pt)
AU (1) AU2007328889B2 (pt)
BR (1) BRPI0720251B8 (pt)
CA (1) CA2668520C (pt)
CL (1) CL2007003516A1 (pt)
CY (1) CY1110706T1 (pt)
DE (1) DE602007006231D1 (pt)
DK (1) DK2086941T3 (pt)
ES (1) ES2344535T3 (pt)
HK (1) HK1137428A1 (pt)
HR (1) HRP20100384T1 (pt)
IL (1) IL199081A (pt)
JO (1) JO2685B1 (pt)
ME (1) ME01073B (pt)
MX (1) MX2009005980A (pt)
NO (1) NO341995B1 (pt)
NZ (1) NZ576673A (pt)
PL (1) PL2086941T3 (pt)
PT (1) PT2086941E (pt)
RS (1) RS51390B (pt)
RU (1) RU2446159C2 (pt)
SI (1) SI2086941T1 (pt)
TW (1) TWI412364B (pt)
WO (1) WO2008068269A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607879T3 (es) 2012-04-27 2017-04-04 Janssen Pharmaceutica N.V. Derivados de quinolina antibacterianos
JP6153604B2 (ja) 2012-04-27 2017-06-28 ヤンセン ファーマシューティカ エヌ．ベー． 抗菌性キノリン誘導体
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
CA2270123A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
ES2236548T3 (es) * 2001-07-31 2005-07-16 Wayne State University Derivados de quinolina y su uso como agentes antitumorales.
DE60332023D1 (de) * 2002-07-25 2010-05-20 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
KR101150172B1 (ko) 2004-01-23 2012-05-25 얀센 파마슈티카 엔.브이. 치환된 퀴놀린 및 마이코박테리아 저해제로서의 용도
ATE444068T1 (de) * 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
MXPA06008596A (es) * 2004-01-29 2006-08-28 Janssen Pharmaceutica Nv Derivados de quinolina para uso como inhibidores micobacterianos.
PT1753427E (pt) * 2004-05-28 2008-07-04 Janssen Pharmaceutica Nv Utilização de derivados quinolina substituídos para o tratamento de doenças micobacterianas resistentes a fármacos
RU2418001C2 (ru) 2004-09-28 2011-05-10 Янссен Фармацевтика Н.В. Домен связывания бактериальной атр-синтазы

Also Published As

Publication number Publication date
ATE465994T1 (de) 2010-05-15
KR20090087071A (ko) 2009-08-14
NO341995B1 (no) 2018-03-12
RU2009125525A (ru) 2011-01-20
CY1110706T1 (el) 2015-06-10
US7998979B2 (en) 2011-08-16
AR064150A1 (es) 2009-03-18
AU2007328889B2 (en) 2012-12-06
RU2446159C2 (ru) 2012-03-27
NZ576673A (en) 2011-09-30
JP2010511670A (ja) 2010-04-15
TW200845987A (en) 2008-12-01
RS51390B (en) 2011-02-28
EP2086941B1 (en) 2010-04-28
IL199081A (en) 2013-08-29
PT2086941E (pt) 2010-07-14
KR101490221B1 (ko) 2015-02-05
SI2086941T1 (sl) 2010-08-31
PL2086941T3 (pl) 2010-10-29
MX2009005980A (es) 2009-06-16
TWI412364B (zh) 2013-10-21
CA2668520A1 (en) 2008-06-12
JO2685B1 (en) 2013-03-03
WO2008068269A1 (en) 2008-06-12
HK1137428A1 (en) 2010-07-30
JP5356245B2 (ja) 2013-12-04
CL2007003516A1 (es) 2008-07-11
BRPI0720251B1 (pt) 2020-10-06
DK2086941T3 (da) 2010-08-09
NO20092540L (no) 2009-09-07
CN101541752A (zh) 2009-09-23
AU2007328889A1 (en) 2008-06-12
ME01073B (me) 2012-10-20
DE602007006231D1 (de) 2010-06-10
CA2668520C (en) 2016-01-26
ES2344535T3 (es) 2010-08-30
EP2086941A1 (en) 2009-08-12
CN101541752B (zh) 2013-07-17
US20100063061A1 (en) 2010-03-11
BRPI0720251A2 (pt) 2014-01-07
HRP20100384T1 (hr) 2010-08-31

Similar Documents

Publication Publication Date Title
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
ATE517882T1 (de) Chinolinderivate
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BRPI0614122A8 (pt) composto derivado de quinolina, composição farmacêutica e uso do referido composto
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BRPI0613999B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
BRPI0719939B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
CY1112230T1 (el) Αντιβακτηριακα παραγωγα κινολινης
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
MX355050B (es) Derivados de quinolina antibacterianos.
BRPI0612534B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
BR112023017040A2 (pt) Derivados de indolina como inibidores de ddr1 e ddr2
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
CY1112027T1 (el) Αντιβακτηριακα παραγωγα κινολινης
BR112014026776A2 (pt) derivados de pirimidina para o tratamento de doenças bacterianas
BR112023002077A2 (pt) Composto e seu uso, composição e formulação farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF